A female patient taking trazodone 150 mg remains depressed; what medication should be added or switched to?

Increase Trazodone Dose or Switch to a Different Antidepressant

For a patient on trazodone 150 mg who remains depressed, you should first increase the trazodone dose to 200-300 mg/day (up to 400 mg/day for outpatients), as 150 mg is merely the starting dose, not a therapeutic dose. If inadequate response persists after 6-8 weeks at optimized dosing, switch to a second-generation antidepressant (SSRI or SNRI) based on side effect profile and patient preference 1, 2.

Why Dose Optimization Comes First

The FDA label explicitly states that 150 mg/day is the initial dose, not the therapeutic target 2. The dose should be increased by 50 mg every 3-4 days, with therapeutic antidepressant doses typically ranging from 150-300 mg/day 3, 4. For outpatients, maximum doses can reach 400 mg/day, and inpatients may receive up to 600 mg/day 2.

Critical pitfall: Trazodone is frequently underdosed in clinical practice. A retrospective study found that initial trazodone doses averaged only 113.7 mg/day (below the recommended 150 mg starting dose), and final doses averaged just 217.9 mg/day—far short of the optimal 250-350 mg/day range 5. This underdosing likely explains the common misconception that trazodone has weaker antidepressant effects than tricyclics.

Dosing Strategy

• Current dose: 150 mg/day (starting dose only)
• Target therapeutic range: 200-300 mg/day for most patients
• Titration: Increase by 50 mg every 3-4 days as tolerated 2
• Maximum outpatient dose: 400 mg/day 2
• Administration: Take shortly after a meal to optimize absorption and reduce side effects 2
• Timing: If drowsiness occurs, give the major portion at bedtime 2

When to Switch Instead

If the patient fails to respond adequately after 6-8 weeks at optimized trazodone dosing (≥250-300 mg/day), modification of treatment is indicated 1. The 2023 American College of Physicians guideline found no efficacy differences between second-generation antidepressants, so switching should be based on:

1. Adverse effect profiles (sexual dysfunction, weight gain, insomnia, GI effects)
2. Cost considerations
3. Patient preferences 6, 1

The 2023 guideline specifically found that various switch strategies (to bupropion SR, escitalopram, duloxetine, sertraline, venlafaxine XR, or vortioxetine) showed similar efficacy in patients who didn't respond to initial antidepressant treatment 6.

Augmentation vs. Switching

For second-step treatment after inadequate response, both augmentation and switching strategies show similar efficacy 6. The STAR*D trial found no significant differences between:

• Switching to another antidepressant (bupropion SR, sertraline, venlafaxine XR)
• Augmenting with bupropion SR or buspirone
• Adding cognitive therapy 6

However, bupropion augmentation had lower discontinuation rates due to adverse events (12.5%) compared to buspirone (20.6%) 6.

Monitoring Requirements

Once you optimize or change treatment:

• Assess within 1-2 weeks of any dose change or new medication 1
• Monitor for suicidal ideation (highest risk in first 1-2 months) 1
• Evaluate therapeutic response at 6-8 weeks 1
• Screen for agitation, irritability, or behavioral changes indicating worsening depression 1

Special Considerations

• Drug interactions: If the patient is on strong CYP3A4 inhibitors, trazodone levels may be elevated; if on strong CYP3A4 inducers, higher doses may be needed 2
• Trazodone advantages: Unlike SSRIs, trazodone effectively treats insomnia (common in depression), has low rates of sexual dysfunction and weight gain, and addresses anxiety/agitation 3, 4, 7
• Discontinuation: If switching away from trazodone, taper gradually rather than stopping abruptly 2